Skip to main content

Stryker Value Stock - Dividend - Research Selection

Stryker

ISIN: US8636671013 , WKN: 864952

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


GMED's Robotics Leasing Shift Could Build Recurring Revenue

2026-05-29
Globus Medical is shifting robotics deals to leases and rentals, aiming to expand its installed base and build recurring revenue streams.

Is Stryker (SYK) Reframing Its Innovation Edge With Pangea And Cybersecurity Investments?

2026-05-29
Stryker recently launched its Pangea Plating System in Europe, a surgeon‑collaborated trauma platform designed to stabilize a wide range of fracture patterns across upper and lower extremities. The system’s use of global anatomical data and variable‑angle plating underscores Stryker’s push to tailor fracture fixation solutions to diverse patient populations and surgeon preferences. Next, we’ll explore how this European Pangea launch, alongside recent cyberattack disclosures, could influence...

Director Of Stryker Sold $96.79M In Stock

2026-05-29

Assessing Stryker (SYK) Valuation After Mixed Q1 Results And Cyberattack Concerns

2026-05-29
Stryker (SYK) is back in focus after mixed first quarter results, a disruptive cyberattack, and a series of analyst updates, even as the company rolls out new products and reorganizes parts of its business. See our latest analysis for Stryker. At a share price of US$307.63, Stryker’s short term share price return has been weak, with the stock down 20.6% over the past 90 days. The 5 year total shareholder return of 29.73% points to longer term gains and suggests recent momentum has faded as...

GMED Growth Drivers After NuVasive and What Q1 Signals

2026-05-28
Globus Medical's Q1 showed margin gains, strong spine and trauma growth, and rising robotics adoption as NuVasive synergies support 2026 targets.

InMode: My Pick For A Major Turnaround In 2026 And 2027

2026-05-28
Discover why InMode Ltd. looks undervalued: strong free cash flow, buybacks, and global growth catalysts—get the latest outlook and act now. Click for more on INMD.

Is Stryker (SYK) One of the Best Medical Technology Stocks to Buy Right Now Despite a Cyberattack?

2026-05-27
Stryker Corporation (NYSE:SYK) is one of the best medical technology stocks to buy right now. On May 12, Argus analyst David Toung cut his price target on Stryker Corporation (NYSE:SYK) to $350 from $435 while keeping a Buy rating. This call followed a cyberattack that upended Stryker’s first quarter and sent its stock to a […]

Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance

2026-05-27
Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.

Stryker Launches Pangea Plating System in Europe for Fracture Fixation

2026-05-27
SYK launches Pangea Plating System in Europe, completing its first London case as it broadens trauma care solutions for many fractures.

Stryker: Reaching Interesting Levels

2026-05-27